Trial Information - Phase III

CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant(AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in patients with HR+/HER2- early breast cancer and a intermediate or high risk of recurrence who have completed definitive locoregional therapy and at least 2 years of adjuvant endocrine therapy without disease recurrence

Protocol ID: D8531C00002

Sponsor: AstraZeneca plc

Status: PENDING OPEN

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at 877-664-7724